SCHEMBL17118715

SCHEMBL17118715

COC(=O)c1cc(Br)c(Cl)cc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
GAA P10253 2/20 0.45
ABL1 P00519 1/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
LMNA P02545 3/20 0.43
SOS1 Q07889 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ALDH1A1 P00352 2/20 0.41
HTT P42858 2/20 0.41
NQO2 P16083 1/20 0.41
TSHR P16473 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
CA12 O43570 4/20 0.39
CA1 P00915 4/20 0.39
CA2 P00918 4/20 0.39
CA9 Q16790 4/20 0.39
CA7 P43166 2/20 0.39
CA14 Q9ULX7 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31487952 1.00 MAPT (0.47) MAPTNPSR1GAAABL1MEN1
SCHEMBL8378560 0.89 GAA (0.49) MAPTNPSR1GAAABL1MEN1
SCHEMBL71501 0.86 GAA (0.52) MAPTNPSR1GAAABL1MEN1
SCHEMBL20045541 0.85 GAA (0.42) MAPTNPSR1GAAABL1MEN1
SCHEMBL747498 0.85 CA1 (0.49) MAPTNPSR1GAAABL1MEN1
SCHEMBL17239465 0.85 ABL1 (0.45) MAPTNPSR1GAAABL1MEN1
SCHEMBL17249571 0.85 MAPT (0.45) MAPTNPSR1GAAABL1MEN1
SCHEMBL31301254 0.85 GAA (0.49) GAAABL1MEN1KMT2ALMNA
SCHEMBL24801432 0.84 GAA (0.45) MAPTNPSR1GAAABL1MEN1
SCHEMBL18981860 0.84 GAA (0.49) MAPTNPSR1GAAABL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3456713-A1 PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES Japan Tobacco Inc. (JP) 2019-03-20 EP disclosed
WO-2018089499-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF NAVITOR PHARMACEUTICALS, INC. 2018-05-10 US disclosed
US-20150266834-A1 TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2015-09-24 US disclosed
US-20150266834-A1 TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF JAPAN TOBACCO INC. (JP) 2015-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150266834-A1 TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF PTGIS, PTGS1, PTGES MAPT 124/4885NPSR1 417/4885GAA 3214/4885
US-20180127370-A1 PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF MTOR, RICTOR, RPTOR MAPT 1388/4885NPSR1 3038/4885GAA 1949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.